AP2817A - Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same

Info

Publication number
AP2817A
AP2817A AP2010005134A AP2010005134A AP2817A AP 2817 A AP2817 A AP 2817A AP 2010005134 A AP2010005134 A AP 2010005134A AP 2010005134 A AP2010005134 A AP 2010005134A AP 2817 A AP2817 A AP 2817A
Authority
AP
ARIPO
Prior art keywords
methods
includingpolymorphs
sulfonamides
arylamino
mek
Prior art date
Application number
AP2010005134A
Other versions
AP2010005134A0 (en
Inventor
Jean-Michel Vernier
Collin Edward Rowlings
Jean-Luc Gi-Rardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of AP2010005134A0 publication Critical patent/AP2010005134A0/en
Application granted granted Critical
Publication of AP2817A publication Critical patent/AP2817A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pest Control & Pesticides (AREA)
  • Hospice & Palliative Care (AREA)
  • Dentistry (AREA)
AP2010005134A 2007-07-30 2008-07-28 Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same AP2817A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number Publication Date
AP2010005134A0 AP2010005134A0 (en) 2010-02-28
AP2817A true AP2817A (en) 2013-12-31

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005134A AP2817A (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same

Country Status (22)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20140098185A (en)
CN (2) CN101808516B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA032294B1 (en)
EC (1) ECSP109910A (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2009129246A2 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
CA3003213C (en) * 2008-09-09 2021-07-20 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
ES2663536T3 (en) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agents that bind to frizzled receptors and uses thereof
AU2010224044A1 (en) * 2009-03-11 2011-09-22 Ardea Biosciences, Inc. Pharmaceutical combinations comprising RDEA119/BAY 869766 for the treatment of specific cancers
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
JP2013508318A (en) * 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト Substituted benzosulfonamide derivatives
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
US20140315929A1 (en) * 2011-04-28 2014-10-23 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
CA2837162C (en) * 2011-05-27 2019-04-02 Bayer Intellectual Property Gmbh Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN104394855A (en) * 2012-05-31 2015-03-04 拜耳医药股份有限公司 Biomarkers for determining effective response of treatments of hepatocellular carcinoma (HCC) patients
EA201492082A1 (en) 2012-06-04 2015-03-31 Фармасайкликс, Инк. CRYSTAL FORMS OF BLUTON TYROSINKINASE INHIBITOR
HRP20240033T1 (en) * 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulation comprising a mek inhibitor
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106535931A (en) * 2014-08-25 2017-03-22 艾慕恩治疗公司 Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MX2019015177A (en) 2017-06-16 2020-02-07 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-m ethoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl )acrylamide and salts thereof.
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (en) * 2024-07-02 2025-09-16 江苏海洋大学 Preparation method and application of metalloprotease 9 epitope imprinting nano-particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545030B1 (en) * 1999-01-13 2003-04-08 Warner-Lambert Company 1-heterocycle substituted diarylamines
US6780870B2 (en) * 2000-02-11 2004-08-24 Smithkline Beecham Corporation Pyrimidine derivatives as selective inhibitors of COX-2
US20040176418A1 (en) * 2000-06-15 2004-09-09 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
DK0810209T3 (en) * 1992-08-25 2002-08-12 Monsanto Co Alpha and beta amino acid hydroxyethylaminosulfonamides for use as inhibitors of retroviral proteases
CN100441176C (en) * 2001-09-24 2008-12-10 杰西·L·S·奥 Methods and compositions for determining chemosensitizing doses of suramin for use in combination therapy
EP1534262A1 (en) * 2002-07-17 2005-06-01 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
KR20130016413A (en) * 2002-07-30 2013-02-14 아에테르나 젠타리스 게엠베하 A drug product of alkylphosphocholines in combination with antitumor medicaments
BRPI0607537A2 (en) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd nanoparticulate quinazoline derivative formulations
EP1876167A4 (en) * 2005-04-22 2010-07-07 Kissei Pharmaceutical Crystal polymorphism of 4 -{2-ý(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino¨ethoxy}-3-isopropyl-3 ,5 -dimethylbiphenylcarboxylic acid hydrochloride
ES2481402T3 (en) * 2005-07-21 2014-07-30 Ardea Biosciences, Inc. MEK N- (arylamino) sulfonamide inhibitors
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd Novel crystals of piperacillin sodium monohydrate and process for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545030B1 (en) * 1999-01-13 2003-04-08 Warner-Lambert Company 1-heterocycle substituted diarylamines
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6780870B2 (en) * 2000-02-11 2004-08-24 Smithkline Beecham Corporation Pyrimidine derivatives as selective inhibitors of COX-2
US20040176418A1 (en) * 2000-06-15 2004-09-09 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist

Also Published As

Publication number Publication date
DOP2010000045A (en) 2010-10-31
EA020624B1 (en) 2014-12-30
KR20140098185A (en) 2014-08-07
EA032294B1 (en) 2019-05-31
JP2017125021A (en) 2017-07-20
EP2184984A1 (en) 2010-05-19
CO6470808A2 (en) 2012-06-29
HK1147396A1 (en) 2011-08-12
AU2008282338A1 (en) 2009-02-05
KR20150091434A (en) 2015-08-10
IL203296A (en) 2017-06-29
BRPI0815659A2 (en) 2014-09-30
CN101808516B (en) 2013-08-28
CN101808516A (en) 2010-08-18
AU2008282338B2 (en) 2015-02-12
NZ582929A (en) 2012-03-30
JP2015078199A (en) 2015-04-23
CN103479604B (en) 2016-08-10
CA2693390C (en) 2017-01-17
AU2015200390B2 (en) 2017-02-23
ECSP109910A (en) 2010-04-30
EA201000268A1 (en) 2010-08-30
KR20100092424A (en) 2010-08-20
MX2010001244A (en) 2010-08-31
CN103479604A (en) 2014-01-01
EA201400552A1 (en) 2014-09-30
JP2010535232A (en) 2010-11-18
WO2009018233A1 (en) 2009-02-05
CR11244A (en) 2010-05-20
AP2010005134A0 (en) 2010-02-28
CA2693390A1 (en) 2009-02-05
JP6309880B2 (en) 2018-04-11
HN2010000203A (en) 2012-11-19
EP2184984A4 (en) 2013-07-24
PH12015501914A1 (en) 2017-07-31
MA31881B1 (en) 2010-12-01
SV2010003469A (en) 2010-04-30
TN2010000049A1 (en) 2011-09-26

Similar Documents

Publication Publication Date Title
AP2817A (en) Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
NO2022013I1 (en) Finerenone and its salts, solvates and solvates of the salts thereof
IL222698A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL192298A (en) Heterocyclic compounds, pharmaceutical acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof
WO2009158571A8 (en) Heteroaryl compounds and uses thereof
DK2074122T5 (en) PYRIDO (2, 3-D) PYRIMIDINON COMPOUNDS AND USE THEREOF AS PI3 INHIBITORS
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
ZA200807263B (en) Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
MY154898A (en) P70 s6 kinase inhibitors
IL189201A0 (en) N-(arylamino)-sulfonamide inhibitors of mek
SI2344486T1 (en) Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
DK2146991T3 (en) Triazolopyridine carboxamide derivatives, preparation of the same as well as therapeutic use thereof
PL1928840T3 (en) 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EP2320738A4 (en) Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
IL209945A0 (en) Novel derivatives of pyrroloindole inhibitors of hsp90; compositions containing same, and use thereof
ZA200702596B (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors
TH0901000961A (en) N-(arylamino)sulfonamide derivatives including polymorphs as MEK inhibitors and constituents, methods of use. and methods for preparing the same substances
EP2213650A4 (en) Substituted diphenylamines as inhibitors of reverse transcriptase, process of preparing them and use thereof